Clinical Trial Update: A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/phase 2 clinical trial update describing a study of HRS-6209 in combination with fulvestrant, letrozole, HRS-8080, or HRS-1358 for advanced unresectab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• HRS-1358 (HRS-1358)
• HRS-6209 (HRS-6209)
• HRS-8080
• Letrozole (letrozole)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Advanced Unresectable or Metastatic Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING